Michael Henderson, BridgeBio CBO

Bris­tol My­ers Squibb catch­es the SHP2 wave in a new col­lab­o­ra­tion deal with Bridge­Bio

Once con­sid­ered “un­drug­gable,” the phos­phatase en­zyme SHP2 has seen re­cent in­ter­est from a suite of Big Phar­mas, in­clud­ing As­traZeneca, Am­gen, No­var­tis and Mer­ck. Now Bris­tol My­ers Squibb is get­ting in on the ac­tion, with a deal to pair its PD-1 su­per­star Op­di­vo with Bridge­Bio’s SHP2 in­hibitor for dif­fi­cult-to-treat can­cers.

BMS and Bridge­Bio took the wraps off the non-ex­clu­sive, co-fund­ed col­lab­o­ra­tion ear­ly Tues­day morn­ing. The “cat­a­lyst,” Bridge­Bio CBO Michael Hen­der­son said, was last year’s vir­tu­al JP Mor­gan con­fer­ence, where the com­pa­nies met to dis­cuss ear­ly pre­clin­i­cal re­sults they were see­ing be­tween SHP2 and im­muno-on­col­o­gy ther­a­pies.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.